Trial Profile
A Phase 2, Randomized, Controlled, Observer Blind, Single Center Study of the Safety, Reactogenicity and Immunogenicity of the NVGH Glycoconjugate Vaccine Against S. Typhi in Children, Older Infants and Infants.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Jan 2020
Price :
$35
*
At a glance
- Drugs Typhoid vaccine Vi conjugate (Primary) ; Pneumococcal vaccine conjugate
- Indications Pneumococcal infections; Typhoid
- Focus Pharmacodynamics
- Sponsors Novartis
- 01 Aug 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 24 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 14 Dec 2011 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.